Answers are grounded in this paper and cite their sources.
The overall survival rate for metastatic osteosarcoma hovers around 20%. Responses to second-line chemotherapy, targeted therapies, and immunotherapies have demonstrated limited efficacy in metastatic osteosarcoma. Our objective is to validate differentially expressed genes and signaling pathways between non-metastatic and metastatic osteosarcoma, employing single-cell RNA sequencing (scRNA-seq) and additional functional investigations. We aim to enhance comprehension of metastatic mechanisms and potentially unveil a therapeutic target.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: